ASMB (STOCKS)
Assembly Biosciences, Inc
$23.340000
+0.380000 (+1.66%)
Prev close: $22.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jason A. Okazaki
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $461.94M
- Employees
- 73
- P/E (TTM)
- -19.12
- P/B (TTM)
- 1.84
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $71.10M |
| Benefits Costs and Expenses | $77.48M |
| Costs And Expenses | $77.48M |
| Nonoperating Income/Loss | $7.16M |
| Operating Expenses | $84.64M |
| Research and Development | $64.86M |
| Other Operating Expenses | $19.78M |
| Operating Income/Loss | -$13.55M |
| Income/Loss From Continuing Operations After Tax | -$6.38M |
| Income/Loss From Continuing Operations Before Tax | -$6.38M |
| Net Income/Loss | -$6.38M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$6.38M |
| Net Income/Loss Available To Common Stockholders, Basic | -$6.38M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.11 |
| Diluted Earnings Per Share | -$0.11 |
| Basic Average Shares | 39,151,402 |
| Diluted Average Shares | 39,151,402 |
| Assets | $235.51M |
| Current Assets | $232.61M |
| Cash | $226.60M |
| Other Current Assets | $6.01M |
| Noncurrent Assets | $2.90M |
| Fixed Assets | $214.00K |
| Other Non-current Assets | $2.68M |
| Liabilities | $36.90M |
| Current Liabilities | $35.00M |
| Accounts Payable | $1.13M |
| Wages | $2.37M |
| Other Current Liabilities | $31.50M |
| Noncurrent Liabilities | $1.90M |
| Equity | $198.61M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $198.61M |
| Liabilities And Equity | $235.51M |
| Net Cash Flow From Operating Activities | -$39.75M |
| Net Cash Flow From Operating Activities, Continuing | -$39.75M |
| Net Cash Flow From Investing Activities | -$125.44M |
| Net Cash Flow From Investing Activities, Continuing | -$125.44M |
| Net Cash Flow From Financing Activities | $172.89M |
| Net Cash Flow From Financing Activities, Continuing | $172.89M |
| Net Cash Flow | $7.71M |
| Net Cash Flow, Continuing | $7.71M |
| Comprehensive Income/Loss | -$6.50M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$6.50M |
| Other Comprehensive Income/Loss | -$19.51M |